ZY, L., YF, Y., Y, G., H, L., MQ, X., M, L., . . . X, Z. (2020). Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid. Dove Medical Press.
Style de citation Chicago (17e éd.)ZY, Li, et al. Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid. Dove Medical Press, 2020.
Style de citation MLA (8e éd.)ZY, Li, et al. Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid. Dove Medical Press, 2020.
Attention : ces citations peuvent ne pas être correctes à 100%.